5 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 6 Phase 1, 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow LY3214996: new trials by email Literature Review of LY3214996 trials Research Report on LY3214996
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers RMC-4630, LY3214996 - Pancreatic Cancer, Colorectal Cancer | Phase 1 | Terminated | The Netherlands Cancer Institute | 24 | 2022-03-31 | 2025-01-24 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. Abemaciclib, LY3214996 - Cancer, Cancer Metastatic | Phase 2 | Terminated | Anita Turk | 16 | 2020-10-05 | 2024-08-07 |
| LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy LY3214996 - Acute Myeloid Leukemia | Phase 1 | Completed | Dana-Farber Cancer Institute | 17 | 2020-07-15 | 2025-05-08 |
| LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients Abemaciclib, LY3214996 - Glioblastoma, GBM | Early Phase 1 | Completed | Nader Sanai | 42 | 2020-07-11 | 2026-03-06 |
| LY3214996 +/- HCQ in Pancreatic Cancer Hydroxychloroquine Sulfate, LY3214996 - Pancreatic Cancer, Advanced Cancer | Phase 2 | Completed | Kimberly Perez, MD | 52 | 2020-05-27 | 2025-02-12 |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies Ibrutinib, LY3214996 - Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia | Phase 1 | Withdrawn | Dana-Farber Cancer Institute | 2020-02-03 | 2020-02-05 | |
| A Study of LY3214996 in Healthy Participants LY3214996, [14C]-LY3214996 - Healthy | Phase 1 | Completed | Eli Lilly and Company | 6 | 2019-08-01 | 2019-10-29 |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer LY3214996, Midazolam, Abemaciclib - Advanced Cancer, Metastatic Melanoma | Phase 1 | Completed | Eli Lilly and Company | 210 | 2016-09-29 | 2022-11-22 |
Colorectal Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Pancreatic Neoplasms (2) · Colonic Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Rectal Neoplasms (1) · Recurrence (1)
Dana-Farber Cancer Institute (2) · Eli Lilly and Company (2) · Anita Turk (1) · Kimberly Perez, MD (1) · M.D. Anderson Cancer Center (1) · Nader Sanai (1) · The Netherlands Cancer Institute (1)
United States (7) · Australia (1) · France (1) · Japan (1) · Netherlands (1)
Anita Turk, MD (1) · Christine M Parseghian, MD (1) · Emile Voest, MD, PhD (1) · Kimberly Perez, MD (1) · Nader Sanai, MD (1) · Rahul Vedula, MD (1) · Steven Treon, MD, PhD (1)
PMID 29808006, PMID 31744895, PMID 36384095
2016 (1), R01CA187238 (1)